Genetron Health to Announce Fourth Quarter and Full Year 2021 Unaudited Financial Results and Host Investor Call on March 29, 2022
March 09 2022 - 4:05PM
Genetron Holdings Limited (“Genetron Health” or the “Company”,
NASDAQ: GTH), a leading precision oncology platform company in
China that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today announced that it will report unaudited financial results for
the fourth quarter and full year ended December 31, 2021 on March
29, 2022 before the US market open.
Management will host a conference call for investors at 8:30
a.m. ET (8:30 p.m. Beijing time) on Tuesday, March 29, 2022. The
conference call can be accessed by dialing the following
numbers:
United States: |
+1-833-239-5565 |
China Domestic: |
400-820-5286 |
Hong Kong: |
+852-3018-6771 |
International: |
+65-6713-5590 |
Conference ID: |
9419319 |
Participants are encouraged to dial into the call at least 15
minutes in advance due to high call volumes.
A simultaneous webcast of the conference call will be available
on the "Events and Presentations" page of the Investors section of
the Company's website. A replay of the webcast will be available
for 30 days following the event. For more information, please
visit ir.genetronhealth.com.
About Genetron Holdings LimitedGenetron
Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH)
is a leading precision oncology platform company in China that
specializes in cancer molecular profiling and harnesses advanced
technologies in molecular biology and data science to transform
cancer treatment. The Company has developed a comprehensive
oncology portfolio that covers the entire spectrum of cancer
management, addressing needs and challenges from early screening,
diagnosis and treatment recommendations, as well as continuous
disease monitoring and care. Genetron Health also partners with
global biopharmaceutical companies and offers customized services
and products. For more information, please visit
ir.genetronhealth.com.
Safe Harbor StatementThis press release
contains forward-looking statements. These statements are made
under the “safe harbor” provisions of the U.S. Private Securities
Litigation Reform Act of 1995. Statements that are not historical
facts, including statements about the Company’s beliefs and
expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties, and a number
of factors could cause actual results to differ materially from
those contained in any forward-looking statement. In some cases,
forward-looking statements can be identified by words or phrases
such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. Further
information regarding these and other risks, uncertainties or
factors is included in the Company’s filings with the SEC. All
information provided in this press release is as of the date of
this press release, and the Company does not undertake any duty to
update such information, except as required under applicable
law.
Investor Relations ContactUS:Hoki LukHead of
Investor RelationsEmail: hluk@genetronhealth.usPhone: +1 (408)
891-9255
Philip Trip TaylorPrinciple | Gilmartin
Groupir@genetronhealth.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024